Tuesday, February 24, 2015 | 8:30 AM - 4:30 PM
Speakers: Chad Cowen (Massachusetts General Hospital), James Inglese (National Center for Advancing Translational Sciences, NIH), J. Keith Joung (Massachusetts General Hospital), Randall Platt (Massachusetts Institute of Technology), Yi Yang (Novartis Institutes for Biomedical Research), Lei (Stanley) Qi (University of California San Francisco)
The emergence of genome editing technologies such as TALEN and CRISPR/Cas9 are revolutionizing our ability to rapidly engineer mammalian systems. This symposium explores the frontiers of genome editing and potential to aid therapeutic development.
Tuesday, March 24, 2015 | 11:45 AM - 4:00 PM
Speakers: P. Jeffrey Conn (Vanderbilt University), Ron Dror (Stanford University), Christopher Fotsch (Amgen), Corey Hopkins (Vanderbilt University), Whitney Nolte (Pfizer)
In this symposium, academic and industry scientists will describe the identification, characterization, and development of PAMs for challenging GPCRs.
Monday, April 27, 2015 | 8:30 AM - 5:00 PM
Speakers: Erwan Bezard (University of Bordeaux),
Patrick Brundin (Van Andel Institute), Ray Chaudhuri (National Parkinson Foundation Centre of Excellence, Kings College Hospital and Kings College, and University Hospital Lewisham), Marie-Francoise Chesselet (David Geffen School of Medicine at UCLA), Maurizio Facheris (Michael J. Fox Foundation for Parkinson's Research), Horacio Kaufmann (NYU Langone Medical Center), Olivier Rascol (Toulouse University Hospital), Daniel Weintraub (University of Pennsylvania)
This symposium will review clinical tools for the diagnosis and treatment of non-motor symptoms of Parkinson's disease, discuss the disease mechanisms, and address preclinical models for the development of new therapeutics.
October 18 - 22, 2015
Global experts explore the biology of globin gene regulation and fetal hemoglobin induction; stem cell transplant, gene therapy strategies, and gene editing; and clinical issues in thalassemia treatment and imaging.
Tuesday, January 27, 2015 | 8:30 AM - 4:30 PM
Keynote Speaker: James W. Mier (Beth Israel Deaconess Medical Center/ Harvard Medical School, Boston, MA)
Speakers: Stephen D. Gillies (Provenance Biopharmaceuticals, Carlisle, MA), Dario Neri (Philogen, Zurich, Switzerland), Jerome Ritz (Harvard Medical School), Gilles Uzé (Université Montpellier II, Montpellier, France), K. Dane Wittrup (Massachusetts Institute of Technology, Cambridge, MA)
Systemic toxicity currently prevents exploiting the potential of many cytokines to treat cancer, viral infections, inflammatory and autoimmune conditions. Targeted delivery of immune-stimulatory or immune-regulatory cytokines offers much promise.
Wednesday, January 21, 2015 | 8:30 AM - 4:00 PM
Speakers: Jasna Brujic (New York University), Bridget Carragher, John Chodera, Oliver Clarke, Erik Debler, Nancy Greenbaum, David Hall, Barry Honig, Jinrang Kim (Columbia University), Nina Liu (Albert Einstein College of Medicine), Patrick Loria (Yale University), Sean McSweeney (Brookhaven National Lab), Clint Potter
The New York Area Structural Biology Discussion Group convenes twice annually and presents talks and poster sessions from graduate students, postdocs, and laboratory heads.
Tuesday, December 9, 2014 | 8:00 AM - 5:00 PM
Speakers: Matthew D. Breyer (Eli Lilly and Company), Frank C. Brosius (University of Michigan Medical School), Benjamin D. Humphreys (Brigham and Women's Hospital), Matthias Meier (F. Hoffmann-La Roche Ltd), Shahnaz Shahinfar (S. Shahinfar Consulting, Inc. and The Children's Hospital of Philadelphia), Katalin Susztak (University of Pennsylvania), Aliza Thompson (Food and Drug Administration)
Identifying and prosecuting drug targets is challenging due to a poor understanding of pathogenesis and few biomarkers. This symposium identifies targets for preventive or therapeutic interventions and discusses challenges in clinical development.
November 11 - 13, 2014
Keynote Speaker:Thomas R. Insel (National Institute of Mental Health)
Speakers: Tracy L. Bale (University of Pennsylvania), Jay Belsky (University of California, Davis), Maureen Black (University of Maryland), Pia Britto (UNICEF), Serena Counsell (King's College London), Martha Farah (University of Pennsylvania), Edward Frongillo (University of South Carolina), Michael Georgieff (University of Minnesota), Takao Hensch (Harvard University), Sharon Lynn Kagan (Columbia University), Patricia Kuhl (Washington University), Ed Lein (Allen Institute for Brain Science), Betsy Lozoff (University of Michigan), Linda Mayes (Yale School of Medicine), Andrew N. Meltzoff (Washington University), Charles A. Nelson (Harvard University and Boston Children's Hospital), Joseph Piven (UNC School of Medicine, CIDD), Dana Suskind (University of Chicago), Nim Tottenham (UCLA)
Discover the latest cognitive neuroscience research on infant and early childhood development; social, family, and nutritional factors that cause lasting changes to the brain; and intervention, education, and policy to help at-risk children.
Keynote Speaker: Thomas R. Insel (National Institute of Mental Health)
This eBriefing explores cognitive neuroscience research on early development, environmental factors that cause lasting changes in the brain, and initiatives to help at-risk children.
Edited by Mone Zaidi
(Mount Sinai School of Medicine, New York, New York)
A new series in Annals, MARROW presents cutting-edge manuscripts on basic, translational, and clinical bone and bone marrow biology and medicine.
Keynote Speaker: The Honorable Patrick J. Kennedy (Former U.S. Representative, Rhode Island; One Mind for Research; Kennedy Forum)
This eBriefing explores the translation of neuroscience breakthroughs into therapies for mental illness. A keynote lecture looks at strategies to dispel stigma surrounding mental illness so that new treatments are accessible to all.
Organizers: John A. Allen (Pfizer), Mercedes Beyna (Pfizer), Bryan L. Roth (University of North Carolina School of Medicine), and Jennifer Henry (formerly at The New York Academy of Sciences)
This eBriefing looks at how to exploit biased ligand signaling at GPCRs to improve therapeutics for cardiovascular and CNS disorders.
October 27, 2009
What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.
Translational Medicine Initiative
The Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.
Learn more at www.nyas.org/TransMed.